, and signiÔ¨Åcant
heterogeneity in the results. In addition to the uncertain
value of routine thromboprophylaxis, there is little data
regarding optimal agents, dose, or duration of thromboprophylaxis if used. We therefore suggest pharmacoprophylaxis in high-risk patients, but with a low certainty of
evidence.
Evidence. Despite the very low incidence of thromboembolic events among patients undergoing endovenous ablation, one